Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...2021222324252627282930...143144»
  • ||||||||||  Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, Combination therapy, Metastases:  Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC. (Pubmed Central) -  Feb 1, 2023   
    P2a
    In the safety analyses (primary analysis), 38 patients (88.4%) had a treatment-related adverse event, of whom 24 (55.8%) had a grade 3 or higher treatment-related adverse event. The combination of avelumab + cetuximab and chemotherapy showed antitumor activity and tolerable safety; however, the ORR was not improved compared with those reported for current standards of care (NCT03717155).
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Enrollment closed, Enrollment change, Trial primary completion date, Metastases:  LCCC1717: Palbociclib and Cetuximab in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Jan 31, 2023   
    P2,  N=24, Active, not recruiting, 
    SEC61G was the center of the molecular network and targeting the E2F1/SEC61G pathway increased the expression level of MHC-I. Recruiting --> Active, not recruiting | N=57 --> 24 | Trial primary completion date: Jan 2023 --> Jan 2026
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Treatment with ERBITAX in Head and Neck Squamous Cell Carcinoma (HNSCC) post platinum and cetuximab () -  Jan 25, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_160;    
    Options include taxanes, cetuximab, capecitabine and methotrexate...Material and Methods We have retrospectively evaluated 18 patients who received platinum (cisplatin or carboplatin) and cetuximab with or without 5-FU as 1L, and after progression, have received the ERBITAX scheme in advanced lines...A retrospective study compared paclitaxel alone Vs...This allows us to continue supporting the use of ERBITAX in advanced lines, even after the use of prior cetuximab and/or IO. This leaves the chance to considering a sequence of EXTREME, Nivolumab and ERBITAX in those patients who are not candidates for IO in 1L (because of CPS<1), or the use of ERBITAX in second line after IO.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Head and Neck Squamous Cell Carcinoma treated with EXTREME protocol followed by nivolumab () -  Jan 25, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_83;    
    The current 1st line recommendation is platinum/fluoropyrimidine/pembrolizumab...All patients received 2nd line treatment: 61.3% nivolumab, 19.4% paclitaxel, 16.1% carboplatin/paclitaxel and 3.2% methotrexate...A favourable disease group of patients may have influenced the present results as most received multiple treatment lines and two patients achieved sCR. Nevertheless, this data substantiates the benefit of immunotherapy in subsequent lines, and validates this option when chemotherapy plus immunotherapy cannot be used in 1stline.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    CLINICAL FACTORS ASSOCIATED WITH BENEFIT TO NIVOLUMAB: REAL-WORLD DATA ANALYSIS () -  Jan 25, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_82;    
    Purpose/Objective Nivolumab has demonstrated overall survival (OS) improvement in patients (pts) with cisplatin-refractory recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)...Up to 38% of pts received treatment after nivolumab (taxane +/- cetuximab: 84%; clinical trial: 20%; carboplatin-5FU: 3%), with an ORR of 31% and no OS differences by regimen received (p = 0.285)...Pts with ECOG?1 and/or who present with irAEs derived greater benefit. .
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Serum proteomics in head and neck cancer - peripheral blood immune response to treatment () -  Jan 25, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_79;    
    The results draw attention to a number of inflammatory proteins that provide insight into the immuno-modulatory effects of cisplatin in head and neck cancer. The results of this study could pave the way for further clinical studies on cisplatin therapeutic effects.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal, Immunomodulating:  Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects. (Pubmed Central) -  Jan 24, 2023   
    Immunological targets have been found effective in recent clinical studies and have shown promising results. This review outlines the important immunological targets and the medications acting on them that have already been explored, are currently under clinical trials and are further being targeted.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal, Metastases:  Current Targeted Therapy for Metastatic Colorectal Cancer. (Pubmed Central) -  Jan 22, 2023   
    This review discusses the up-to date molecular evidence of targeted therapy for mCRC and summarizes the Food and Drug Administration-approved targeted drugs including the results of clinical trials. We also explain their mechanisms of action and how these affect the choice of a suitable targeted therapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Preclinical, Journal, Biopsy:  Establishment of Mucoepidermoid Carcinoma Cell Lines from Surgical and Recurrence Biopsy Specimens. (Pubmed Central) -  Jan 22, 2023   
    Interestingly, EGFR dependency for cell growth decreased in AMU-MEC-R1 and AMU-MEC-R2 but was retained in AMU-MEC1. These cytogenetic and biochemical findings suggest that the established cell lines can be used to investigate the disease progression mechanisms and develop novel therapeutics for MEC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells. (Pubmed Central) -  Jan 21, 2023   
    The novel quinoin cetuximab immunoconjugate showed a significant dose-dependent cytotoxicity towards GEO-CR cells, achieving IC values of 27.7 nM (~5.0 μg/mL) at 72 h compared to cetuximab (IC = 176.7 nM) or quinoin (IC = 149.3 nM) alone assayed in equimolar amounts. These results support the therapeutic potential of quinoin cetuximab immunoconjugate for the EGFR targeted therapy, providing a promising candidate for further development towards clinical use in the treatment of cetuximab-resistant metastatic colorectal cancer.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. (Pubmed Central) -  Jan 17, 2023   
    Currently, trials are ongoing to include immune checkpoint inhibition in the (neo)adjuvant treatment of HNSCC as well as in novel combinations with other drugs in the recurrent/metastatic setting to improve response rates and survival and help overcome resistance mechanisms to immune checkpoint blockade. This article provides a comprehensive review of the management of head and neck cancers in the current era of immunotherapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, Imbruvica (ibrutinib) / AbbVie, J&J
    Trial completion date, Trial primary completion date, Combination therapy, IO biomarker, Metastases:  Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC (clinicaltrials.gov) -  Jan 17, 2023   
    P2,  N=5, Active, not recruiting, 
    This article provides a comprehensive review of the management of head and neck cancers in the current era of immunotherapy. Trial completion date: May 2023 --> May 2024 | Trial primary completion date: Jan 2022 --> Jan 2024
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, BRCA Biomarker, Metastases:  A study of gene variation in All-RAS wild-type metastatic colorectal cancer and its correlation with cetuximab. (Pubmed Central) -  Jan 14, 2023   
    The PFS and OS of mCRC patients with all-RAS wild-type and no combined mutations treated with cetuximab were not better than those of patients with combined mutations. Compared to mCRC patients with all-RAS wild-type and oncogenic driver gene mutations, cetuximab significantly prolonged the PFS of all-RAS wild-type patients with the tumor suppressor gene mutations.